Monalizumab Antibody

SKU: orb1980751

Description

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

Research Area

Cell Biology, Immunology & Inflammation

Images & Validation

−

Key Properties

−

CAS Number	1228763-95-8
MW	147 kDa (average)
Purity	95.00%
Target	IFNAR,Chk

Bioactivity

−

In Vivo	Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14 the results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor model. Read more...
In Vitro	Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14 the results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor model. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Disclaimer	For research use only

Alternative Names

−

IFNAR, Checkpoint Kinase (Chk)

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Quick Database Links

Gene Symbol

IFNAR,Chk

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols